Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.

丙酸氟替卡松 医学 氟替卡松 哮喘 药代动力学 临床试验 吸入器 早晨 药品 药理学 内科学 麻醉
作者
Izabela R. Kuprys-Lipinska,Damian Tworek,Francis Vanderbist,Małgorzata Bocheńska-Marciniak,Piotr Kuna
出处
期刊:PubMed [National Institutes of Health]
卷期号:81 (6): 527-36 被引量:2
链接
标识
摘要

INTRODUCTION: Inhaled fluticasone is used in the treatment of chronic bronchial asthma. Its high efficacy and good safety profile have been proven by clinical trials and observations. Its unique pharmacokinetic properties make it distinguishable from other drugs from this group. In vitro tests run on an artificial model of the airways and pharmacokinetic studies conducted on healthy volunteers have shown that the new formulation of this drug is outstanding due a twofold better lung deposition, compared to the reference medicine. The aim of this study was to evaluate the efficacy and safety of the new formulation of fluticasone propionate administered through new generation cyclohaler (CNG), compared to original fluticasone administered through dry powder inhaler (DPI) in patients with chronic moderate asthma. MATERIAL END METHODS: The study included 457 patients. 376 subjects were randomized to one out of the three groups: 127 subjects--to the group treated with the new formulation of fluticasone at a dose of 125 μg BID, 125 subjects--to the group treated with new formulation of fluticasone at a dose of 250 μg BID, and 124 subjects--to the group treated with the reference drug--fluticasone DPI 500 μg BID. At the beginning of the study, the groups did not differ in demographical or clinical aspects. Active therapy lasted 12 weeks. The primary endpoint was a mean change in morning PEF during a 12-week course of therapy (ΔmPEF of 15 L/min was considered as statistically significant). Additionally, other functional parameters of the respiratory system--clinical symptoms and the use of rescue drugs were studied. During the whole study the safety of patients was monitored by recording adverse events; in addition, a systemic exposure to fluticasone was evaluated by testing the changes of cortisol in serum and in a 24-hour collection of urine in a subgroup consisting of 45 patients. Statistical analysis was conducted on both groups: intention-to-treat (ITT) and per protocol (PP). RESULTS: In PP as well as in ITT analysis, a mean change in morning PEF at the end of the therapy in comparison with the initial period was statistically significant in all therapeutic groups. The efficacy of the treatment with fluticasone at doses of 125 μg BID and 250 μg and the reference medicines did not differ statistically significantly after a 12-week course of therapy or during the whole period of treatment. During the study, significant improvement in the range of other functional parameters such as evening PEF, FEV₁, clinical symptoms and the use of rescue drugs was observed in all therapeutic groups, without significant differences in efficacy between the study groups. The comparison of efficacy of fluticasone at a dose of 125 μg BID with the generic product at a dose of 250 μg BID showed a weak dose-response relationship concerning the change in morning PEF, which arises from the almost flat dose-response curve in the range of medium and high doses for this drug. No significant quantitative or qualitative differences were shown between the groups in the recorded adverse events, qualified as related to treatment with fluticasone. There were no significant changes revealed in cortisol concentration in serum or in a 24-hour collection of urine between the initial level and the final visit in any of the groups. CONCLUSIONS: Fluticasone administered through the new generation cyclohaler, compared to original fluticasone DPI, allows a twofold reduction in drug dose, retaining in new formulation clinical efficacy that corresponds to the reference drug at twice the dose. New formulation of fluticasone administered through the new generation cyclohaler has a safety profile clinically comparable to the reference drug.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小星星发布了新的文献求助10
刚刚
菠菜的应助被feather采纳,获得10
刚刚
ykyk0927完成签到 ,获得积分10
1秒前
2秒前
wumting完成签到 ,获得积分20
2秒前
斯文的道罡完成签到,获得积分10
3秒前
3秒前
开心的颤发布了新的文献求助10
3秒前
3秒前
平若颜完成签到,获得积分10
4秒前
从容的小蜜蜂完成签到 ,获得积分10
4秒前
5秒前
小狗发布了新的文献求助10
6秒前
桐桐的应助被小朋友采纳,获得10
6秒前
milai发布了新的文献求助10
6秒前
achilles完成签到,获得积分10
6秒前
share完成签到 ,获得积分10
6秒前
7秒前
8秒前
null的应助被Nowaki采纳,获得10
8秒前
8秒前
9秒前
9秒前
Nole的应助被Zzei采纳,获得30
10秒前
许娜发布了新的文献求助10
10秒前
赘婿的应助被milai采纳,获得10
10秒前
纯情的阁的应助被mmmm采纳,获得310
10秒前
11秒前
研友_VZG7GZ的应助被吴陈采纳,获得10
12秒前
yfx发布了新的文献求助30
13秒前
JamesPei的应助被暮离采纳,获得10
13秒前
14秒前
14秒前
14秒前
15秒前
15秒前
温骐华发布了新的文献求助10
15秒前
包容大象完成签到,获得积分10
17秒前
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163664
求助须知:如何正确求助?哪些是违规求助? 9557817
关于积分的说明 21741980
捐赠科研通 7754358
什么是DOI,文献DOI怎么找? 3428338
关于科研通互助平台的介绍 2553000
邀请新用户注册赠送积分活动 2472943